Why Cronos (TSX:CRON) Stock Might Be the Top Pot Investment of 2020

Learn why a partnership with Altria Group Inc (NYSE:MO) should propel Cronos Group Inc (TSX:CRON)(NYSE:CRON) stock higher.

| More on:
Modern buildings in business district

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

It’s time to invest in pot stocks again. After a difficult 2019, the market is finally regaining its footing, with many top stocks eking out small gains to start the year.

Yet the year ahead won’t look anything like the bull market of 2018, where any company even remotely related to marijuana experienced an exponential rise in their share prices. Instead, we’ll likely see a more rational rise, with upside accruing the companies that are making real progress and early traction.

When looking at the lessons learned over the past 18 months, several key indicators suggest that Cronos Group Inc (TSX:CRON)(NYSE:CRON) could be the best-performing pot stock of 2020.

This is what matters

If you don’t have a partner, the year ahead could be difficult. At least that will be the case for pot stocks. For proof, take a look at what happened to Green Organic Dutchman Holdings Ltd (TSX:TGOD).

In 2018, the company boasted a $1 billion market cap, spurred by its recent partnership with Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB), another multi-billion dollar pot firm.

The deal called for Aurora to assist Green Organic with its infrastructure build out, as well as committed it to buying a huge chunk of Green Organic’s cannabis production.

On paper, the deal was perfect. “Teaming up with Aurora, the industry’s innovation leader, provides us with a stable, supportive shareholder, through whom we have access to best-in-class technologies and industry know-how, which we believe will significantly accelerate our time to market,” said Csaba Reider, President of Green Organic.

Last year, everything fell apart as Aurora pulled out of the deal, opting instead to source its organic cannabis internally.

Suddenly, Green Organic was stuck between a rock and a hard place. Within a few quarters, it would begin ramping up cannabis production aggressively. Following Aurora’s withdrawal, however, it no clear buyers.

Today, shares have fallen more than 90% from their peak, assigning the company a valuation of just $210 million. Green Organic’s future remains shrouded in doubt.

The lesson here is simple: If you want the market’s trust, have a committed partner willing to invest significant resources to make your cannabis strategy a success.

A most powerful partner

Fortunately, Cronos has one of the most powerful partners imaginable: $100 billion tobacco behemoth Altria Group Inc (NYSE:MO).

Altria has already done what every cannabis stock today is attempting to do.

In the 1970s, the cigarette industry was ripe with competition and regulation. Over the next few decades, Altria helped consolidate the entire market.

Today, it sells more than 50% of cigarettes in the U.S. under world-renowned brands such as Marlboro. Long-term investors have experienced a total return of more than 20,000%.

After buying more than $2 billion of Cronos stock, as well as making the company its exclusive cannabis partner, Altria is here to stay. If there’s any company in the world capable of creating the next cannabis behemoth, it would be Altria.

If we’ve learned anything over the last 18 months, it’s that partnerships will be a major factoring in whether a pot stock sinks or swims. I can’t think of a stronger tie-up than the Cronos-Altria partnership.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Vanzo has no position in any stocks mentioned. 

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »